TP53 and cancer: After applying the selective proteasome inhibitor (MG132), we monitored the levels of the p53-ubiquitin complex and found that the formation of the complex was dramatically decreased in the Ti0.8O2 nanosheet-treated cancer cells (Figure 8D,E).